1938 – First Scientific CFF Study

1955 – The CF Foundation is incorporated. The median survival for people born with CF is 3-5

1961 – The Care Center Network is formed

1962 – The median survival for CF patients is 10

1978 – More than 100 Foundation supported Care Centers are treating CF Patients

1989 – The defective CF gene is discovered

1993 – Pulmozyme is FDA approved as the first CF specific drug

1997 – TOBI is FDA approved reducing hospital stays and improving lung function

2002 – Azithromycin is found to improve lung health in CFF Supported Studies

2002 – The median survival for CF patients is 31

2004 – Foundation supported studies find hypertonic saline helps clear mucus, improve lung function and reduce hospital stays

2007 - VX-770, an oral drug in development by Vertex Pharmaceuticals, Inc. that works at the cellular level to correct the CF defect enters clinical trials

2007 – Vertex begins testing VX-809 a second drug to address the underlying cause of CF

2010 – The FDA approves Cayston as a much needed antibiotic alternative for CF patients

2012 – The FDA approves Kalydeco (VX-770) for patients with the G551D mutation (about 4% of the CF population)

2013 – Vertex begins Phase 3 trials of Kalydeco and VX-809 in people with two copies of the most popular CF mutation – Delta F508

2014 – The FDA approves Kalydeco for eight additional CF mutations

2014 – CF patients are living well into their 30's, 40's and beyond

2015 – The FDA approves Kalydeco for ages 2+ with the G551D mutation

2015 – the FDA approves Orkambi (formally VX-809) for people with two copies of the F508del mutation ages 12 and older, representing nearly one-third of the CF population in the United States — or about 8,500 people

CYSTIC FIBROSIS FOUNDATION
ADDING TOMORROWS

What Is Cystic Fibrosis?

Cystic fibrosis is a life-threatening genetic disease that affects about 30,000 children and adults in the United States and 70,000 people worldwide. A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that:

- clogs the lungs and leads to life-threatening lung infections; and
- obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food.

In the 1950s, few children with cystic fibrosis lived to attend elementary school. Today, advances in research and medical treatments have further enhanced and extended life for children and adults with CF. Many people with the disease can now expect to live into their 30s, 40s and beyond.

Mission

The mission of the Cystic Fibrosis Foundation, a nonprofit donor-supported organization, is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatments, and ensuring access to high quality, specialized care.

When the CF Foundation was established in 1955, most children with CF did not live past elementary school. Due in large part to the Foundation's aggressive investments in innovative research and comprehensive care, today, many people with CF are living into their 30s, 40s and beyond.

A Model of Innovation

The CF Foundation comprises a cohesive team of individuals working together — patients, their families and friends, medical professionals, researchers, donors, volunteers and staff —all who will not rest until a cure is found.

The Foundation's business model has been recognized by the National Institutes of Health and by publications such as *Forbes*, *The New York Times*, *The Wall Street Journal* and *BusinessWeek*.

Raising Funds, Raising Hope

The Foundation receives no federal funding, and cystic fibrosis is an orphan —or rare —disease, so the Foundation depends on the generosity of individual donors and corporations to support its lifesaving mission.

More than 250,000 dedicated volunteers devote their time and talents to help raise funds for CF research and medical programs. They are the engine that powers the CF Foundation, and their ongoing support makes progress possible.
Each year, more than 500 sites across the country host the Foundation's Great Strides walks, which raise millions of dollars for cystic fibrosis research and care programs. The Foundation's 76 chapters also host thousands of other special fundraising events year-round, such as dinner dances, galas, and golf and fishing tournaments.

Financial support from donors is critical to the Foundation's success. Donors who give to the CF Foundation can be sure that their contributions will be used wisely. Having met the Better Business Bureau's standard of good giving for a charitable organization, the CF Foundation bears the BBB's Wise Giving Alliance seal.